Sab Biotherapeutics, Inc. · NASDAQ:SABS
Vivo Opportunity Fund Holdings, L.P. reported a 9.99% stake in Sab Biotherapeutics, Inc. (Schedule 13G)
Event Sep 29, 2025 · Filed Oct 3, 2025
Vivo Opportunity Fund Holdings, L.P. reported a 9.99% stake in Sab Biotherapeutics, Inc., 25,931,000 shares, as a passive investor on Sep 29, 2025. Filed Oct 3, 2025 (Schedule 13G).
- Stake
- 9.99%
- Shares
- 25,931,000
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 9.99% | 25,931,000 |
| Vivo Opportunity, LLC | 9.99% | 25,931,000 |
| Vivo Opportunity Cayman Fund, L.P. | 9.99% | 2,619,000 |
| Vivo Opportunity Cayman, LLC | 9.99% | 2,619,000 |
Source
Related
- Sab Biotherapeutics, Inc.
- Vivo Opportunity, LLC
- Sab Biotherapeutics, Inc. shareholders
- Schedule 13G/A · Vivo Opportunity, LLC · Aug 14, 2026
- Form 4 · Kropotova Alexandra · Sep 18, 2026
- Schedule 13G/A · Woodline Partners LP · Aug 14, 2026
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Schedule 13G/A · Caligan Partners LP · Aug 14, 2026
- Schedule 13G/A · Commodore Capital LP · Aug 14, 2026